Condiciones de salud que ganoderma puede ayudar a apoyar.
A double-blind crossover RCT in 42 healthy volunteers demonstrated Ganoderma lucidum significantly improved plasma antioxidant capacity, glutathione levels, and reduced oxidative damage biomarkers. A 2025 meta-analysis of 17 RCTs confirmed a significant increase in glutathione peroxidase activity.
A pilot RCT in breast cancer patients found that Ganoderma lucidum spore powder significantly reduced self-reported anxiety scores alongside fatigue improvements. Preclinical data and a Cochrane-style systematic review protocol under development further support anxiolytic potential. Evidence remains preliminary and largely confined to disease-specific populations.
Ganoderma lucidum triterpenes inhibit angiotensin-converting enzyme (ACE) in vitro and have shown blood pressure-lowering effects in some earlier human trials, though a well-designed 16-week RCT and 2025 meta-analysis found no significant overall effect. Traditional use for hypertension is extensive.
Multiple human RCTs and a 2025 meta-analysis of 17 RCTs (n=971) have examined Ganoderma's effects on blood glucose. Results are mixed: some smaller trials report reductions in HbA1c and fasting glucose in type 2 diabetes patients, while a well-designed 16-week RCT found no significant effect. Preclinical evidence for AMPK-mediated insulin sensitisation is robust.
Animal studies consistently show Ganoderma lucidum lowers total and LDL cholesterol and triglycerides. Earlier human trials reported positive effects but were methodologically weak; a well-designed 16-week RCT and 2025 meta-analysis found no significant overall effect on lipid profiles in humans.
A double-blind RCT of Ganopoly in 132 neurasthenia patients showed significant reduction in fatigue and improvement in well-being over 8 weeks. A pilot RCT in breast cancer patients also demonstrated significant fatigue reduction with Ganoderma spore powder.
A 2025 systematic review (23 preclinical studies) confirmed that Ganoderma lucidum triterpenes significantly reduce TNF-α, IL-1β, and IL-6 via MAPK and NF-κB pathway downregulation. Beta-D-glucan polysaccharides also modulate TLR-mediated inflammatory signalling. Human RCT data on inflammatory markers remain limited but directionally consistent.
Ganoderma lucidum spore extract significantly prevented learning and memory impairment in a rat Alzheimer's disease model via neuroinflammation suppression. A Cochrane-style systematic review protocol for human RCTs on the cognitive-impairment continuum has been formally registered.
A pilot RCT in breast cancer patients found significantly less self-reported depression with Ganoderma spore powder after 4 weeks. A Cochrane-style systematic review protocol covering mood disorders including depression has been formally registered. Serotonergic pathway upregulation provides a plausible mechanism.
An 8-week double-blind RCT of Ganopoly (polysaccharide extract) in 132 neurasthenia patients showed significant reductions in the sense of fatigue and improved well-being versus placebo. A pilot RCT in breast cancer patients also demonstrated significant fatigue improvements with Ganoderma spore powder.
Preclinical studies show Ganoderma lucidum water extract reverses high-fat diet-induced gut dysbiosis, decreasing Firmicutes-to-Bacteroidetes ratios, reducing endotoxin-bearing Proteobacteria, and maintaining intestinal barrier integrity. Gut microbiota modulation also appears to mediate its sleep-promoting effects via serotonin.
Preclinical evidence shows Ganoderma lucidum promotes sleep and modulates mood via a gut microbiota-serotonin axis, with GLAA extract increasing hypothalamic 5-HT levels through changes in gut bacteria and metabolites. This positions G. lucidum at the intersection of the gut-brain axis.
Ganoderma lucidum triterpenes inhibit ACE and platelet aggregation in vitro, and animal studies demonstrate cardioprotective effects. Human studies on cardiovascular risk factors show mixed results, with the best-designed RCT finding no significant effects on blood pressure, lipids, or glucose in metabolic syndrome patients.
Traditional Chinese medicine has long employed Ganoderma for insomnia ('An-Shen' sedative effect). Preclinical studies confirm sleep-latency reduction and increased sleep duration via GABAergic and serotonergic mechanisms. A small clinical trial in 60 insomnia patients, and a neurasthenia RCT, provide initial human support.
Preclinical evidence shows Ganoderma lucidum extract activates AMPK to improve insulin sensitivity, and human clinical data show reductions in HOMA-IR. Some RCT evidence in type 2 diabetes supports improvements in fasting glucose and HbA1c, though a larger 16-week RCT found no effect.
Traditional Chinese medicine has used Ganoderma to treat nephritis and support kidney function. A 2025 meta-analysis of 17 human RCTs found a significant reduction in serum creatinine with Ganoderma supplementation, and preclinical studies show renal protection.
Ganoderma lucidum has well-documented hepatoprotective properties supported by both preclinical and human evidence. A double-blind crossover RCT in 42 healthy volunteers showed significant improvements in antioxidant capacity and liver enzyme markers, with reversal of mild fatty liver on ultrasound.
Ganoderma lucidum (reishi) is a medicinal mushroom with 2,000+ years of TCM use as a lung tonic. Its triterpenoids inhibit histamine and leukotriene release; polysaccharides modulate immune responses in the airway. Preclinical evidence supports use in asthma and respiratory infection; it appears in clinical lung support formulations.
Preclinical evidence shows Ganoderma lucidum spore extract prevents learning and memory impairment in a rat model of sporadic Alzheimer's disease, acting via inhibition of NF-κB/NLRP3 neuroinflammation. A Cochrane-style systematic review protocol has been registered to evaluate human RCT evidence for cognitive decline.
A dedicated 16-week double-blind RCT in 84 patients with type 2 diabetes and metabolic syndrome tested Ganoderma lucidum for metabolic syndrome risk factors. A 2025 meta-analysis of 17 RCTs found significant BMI reduction. Preclinical data on lipid, glucose, and inflammatory components of metabolic syndrome are extensive.
Ganoderma lucidum triterpenes exhibit 5α-reductase inhibitory activity and inhibit growth, migration, and invasion of prostate cancer cell lines in vitro. A clinical trial also found a small but statistically significant reduction in prostate volume in BPH patients.
A double-blind, placebo-controlled, dose-ranging clinical trial (registered in Cochrane Central) found a G. lucidum extract significantly reduced prostate volume in BPH patients. G. lucidum triterpenoids inhibit 5α-reductase, the enzyme that drives BPH.
Preclinical studies show Ganoderma extract prolongs total sleep time and increases non-REM sleep in rodent models through GABAergic potentiation and serotonergic pathway upregulation. A rat Alzheimer's model study demonstrated significant improvements in both NREM and REM sleep duration.
Preclinical studies demonstrate that Ganoderma extract significantly shortens sleep latency (time to fall asleep) through GABAergic and serotonergic mechanisms, and via gut microbiota-mediated serotonin signalling. Traditional Chinese medicine describes a sedative 'An-Shen' effect for insomnia.
Multiple preclinical studies and a neurasthenia RCT support Ganoderma lucidum's ability to improve overall sleep quality. Mechanisms include GABAergic potentiation, serotonin pathway upregulation via gut microbiota, and suppression of neuroinflammation. The evidence is strongest in preclinical models but directionally supported by clinical findings in disease-affected populations.
Ganoderma lucidum has documented adaptogenic properties in TCM and is associated with reduction of fatigue and improved well-being in a clinical neurasthenia RCT. The breast cancer pilot RCT also showed reduced anxiety and depression—stress correlates—alongside fatigue improvements.
Animal models consistently show Ganoderma lucidum extract reduces serum triglycerides. Some earlier human trials reported triglyceride reductions, but larger RCTs and a 2025 meta-analysis found no significant overall effect. Mechanistic data include inhibition of VLDL secretion and lipid accumulation in the liver.
A double-blind, placebo-controlled, dose-ranging clinical trial (Cochrane Central registered) found a Ganoderma-containing extract significantly reduced prostate volume in BPH patients. G. lucidum's 5α-reductase inhibitory activity provides a mechanistic basis for improving urinary symptoms.
Ganoderma lucidum triterpenoids show documented anti-HIV-1 protease activity via inhibition of lanostane triterpenes, and polysaccharides stimulate innate antiviral immune responses including NK cell activation and interferon-gamma production. Traditional use includes antiviral applications, and modern reviews confirm this activity.
Traditional Asian medicine has used Ganoderma lucidum to treat arthritis for centuries. A 2025 meta-analysis of RCTs included rheumatoid arthritis as a subgroup condition, and the 2025 triterpene systematic review noted anti-inflammatory mechanisms relevant to joint inflammation.
Ganoderma lucidum has a long traditional use for cough and asthma relief in Chinese medicine, described as 'tonifying the lung.' Preclinical evidence shows polysaccharides downregulate alveolar macrophage signalling in asthmatic rats and modulate Th2 immune responses in allergic asthma models.
Ganoderma lucidum is documented in traditional Asian medicine for autoimmune-related conditions including autoimmune hepatitis and arthritis. Preclinical evidence shows it modulates T-cell and B-cell responses, regulates cytokine production, and has complement-inhibitory properties relevant to autoimmune pathology.
Ganoderma lucidum has a documented traditional Chinese medicine use for chronic bronchitis, with antitussive and bronchodilatory pharmacological properties identified in preclinical studies. Modern reviews affirm its potential for bronchitis management based on its anti-inflammatory and respiratory effects.
Ganoderma lucidum has been used for over two millennia in traditional Chinese medicine as a longevity tonic, recorded in Shennong's Herbal Classic (Dong Han Dynasty, ~25–220 AD) as a top-grade medicine promoting health and long life. Modern research identifies antioxidant, immunomodulatory, and hepatoprotective properties as plausible mechanisms.
Volver